Durvalumab After chemoRadioTherapy for NSCLC patients Updates

December 2023
The enrolment in the DART study is now stopped.

In total 123 patients were enrolled. Due to patients withdrawn before start of durvalumab (because of screen failure, withdrawal of consent, SAE etc. ), we ended up with 50 PDL1 pos patients and 36 PDL1 neg patients.

19. June 2023
115 patients are per today enrolled in the DART study, however due to screen failures, withdrawals etc, we still need patients to reach our goal of 100 evaluable patients.

Recruitment of PDL1 positive patients are now closed.
We still need 16 PDL1 negative patients. Please keep in mind that the study drug (durvalumab) is free when patients are enrolled in the study and the patients are offered treatment that is not otherwise provided to them.

Recruitment will continue until December 15 2023.

All 10 sites are recruiting (Oslo university hospital, Stavanger university hospital, Haukeland university hospital, St, Olavs hospital and University Hospital in North-Norway), Finland (Tampere, Turku and Oulu), Lithuania and Estonia.

24. November 2022
100 patients are enrolled in the DART study, however due to screen failures, withdrawals etc, we still need 25-30 more patients to reach our goal of 100 evaluable patients. All 10 sites are recruiting (Oslo university hospital, Stavanger university hospital, Haukeland university hospital, St, Olavs hospital and University Hospital in North-Norway), Finland (Tampere, Turku and Oulu), Lithuania and Estonia.

15. November 2022
A total of 100 patients are included in the trial, of which 23 must be replaced. As of today, 2 patients with PD-L1 positive tumour and 21 with PD-L1 negative tumour remain to be included.

14 January 2022
68 patients are enrolled in the DART study, however due to screen failures, withdrawals etc, we still need 45 patients to reach our goal of 100 evaluable patients. All 10 sites are recruiting (Oslo university hospital, Stavanger university hospital, Haukeland university hospital, St, Olavs hospital and University Hospital in North-Norway), Finland (Tampere, Turku and Oulu), Lithuania and Estonia, and we aim to reach our goal early 2023.

7 September 2021
All 10 sites in the DART study are now enrolling patients (Oslo university hospital, Stavanger university hospital, Haukeland university hospital, St, Olavs hospital and University Hospital in North-Norway), Finland (Tampere, Turku and Oulu), Lithuania and Estonia.

In total 57 patients are now enrolled in the study, however due to screen failures, withdrawals etc, we still need to enroll 55 more patients to reach the planned number of 100.

21 April 2021
Turku University Hospital is now ready for including patients in the DART study as the last site. In total 10 sites are now open for enrolment of patients in Norway (Oslo University Hospital, Stavanger University Hospital, Haukeland University Hospital, St, Olavs Hospital and University Hospital in North-Norway), Finland (Tampere, Turku and Oulu), Lithuania and Estonia.

In total 39 patients are now enrolled in the study out of totally 100.

04 February 2021
Haukeland University Hospital, Bergen, Norway and Tampere University Hospital, Tampere, Finland are now ready for including patients in the DART trial.
In total 22 patients are included in the trial out of total 100.

St. Olavs university hospital in Trondheim enrolled their first patient 16 November 2020 and The University Hospital in North Norway enrolled their first patient 16 December 2020. Then 4 Norwegian sites have started enrolment (Oslo university hospital, Stavanger university hospital, St. Olavs university hospital and University hospital in North Norway). We are waiting for Haukeland university hospital to open soon.

In addition we have open sites in Finland (Oulu), Estonia and Lithuania. Site Tampere in Finland will open in January 2021.

29 October 2020: University Hospital in North of Norway, Tromsø, Norway Oulu University Hospital, Oulu, Finland, Northern Estonia Medical Centre, Tallin, Estonia and National Cancer Institute, Vilnius, Lithuania are initiated as study sites and will start inclusion of patients

10 September 2020: Oslo University Hospital started inclusion in May 2020 and the University Hospital of Stavanger has started inclusion.